← Back to Search

Behavioral Intervention

HERS Program for Cervical Cancer

N/A
Waitlist Available
Led By Suzanne M Miller, PhD
Research Sponsored by Fox Chase Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Display current evidence or have a history of positive invasive carcinoma of the cervix
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 15 months post-baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a program called the Health Enhancement Resource System (HERS) to see if it helps women follow up on abnormal test results. The program uses text messages to help women overcome barriers and

Who is the study for?
This trial is for women who have had abnormal cervical cancer screening results. It's designed to help them follow up on their care using text messages and phone calls. Women must be able to receive texts and calls, but can't join if they are already following a similar program or have conditions that interfere with study participation.
What is being tested?
The trial tests the Health Enhancement Resource System (HERS), which uses texts and health coaching calls to encourage women to follow up after an abnormal cervical screening result. The effectiveness of HERS at different stages (1-4) with or without Health Coaching (HC) compared to standard care is being studied.
What are the potential side effects?
Since this intervention involves communication rather than medication, there aren't typical drug side effects. However, participants may experience increased anxiety or stress from more frequent reminders about their health condition.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have or had cervical cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 15 months post-baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 15 months post-baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Attendance at baseline colposcopy appointment
Secondary study objectives
Attendance at 12-month follow-up appointment

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

13Treatment groups
Experimental Treatment
Group I: Stage, 2, and 3 HERS + Stage 4 HERS+HCExperimental Treatment4 Interventions
Start with Stage 1 HERS intervention; patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS intervention. Continue with Stage 3 HERS intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS+HC intervention.
Group II: Stage 1, 3, and 4 HERSExperimental Treatment3 Interventions
Start with Stage 1 HERS intervention; patient attends baseline colposcopy appointment, no Stage 2 intervention. Continue with Stage 3 HERS intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS intervention.
Group III: Stage 1, 2, and 3 HERSExperimental Treatment3 Interventions
Start with Stage 1 HERS intervention; patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS intervention. Continue with Stage 3 HERS intervention; patient attends 12-month follow-up appointment, no Stage 4 intervention.
Group IV: Stage 1, 2, 3, and 4 HERSExperimental Treatment4 Interventions
Start with Stage 1 HERS intervention; patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS intervention. Continue with Stage 3 HERS intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS intervention.
Group V: Stage 1 and 3 SoC + Stage 4 HERSExperimental Treatment3 Interventions
Start with Stage 1 Standard of Care; patient attends baseline colposcopy appointment, no Stage 2 intervention. Continue with Stage 3 Standard of Care; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS intervention.
Group VI: Stage 1 and 3 SoCExperimental Treatment2 Interventions
Start with Stage 1 Standard of Care; patient attends baseline colposcopy appointment, no Stage 2 intervention. Continue with Stage 3 Standard of Care; patient attends 12-month follow-up appointment, no Stage 4 intervention.
Group VII: Stage 1 and 3 HERS + Stage 4 HERS+HCExperimental Treatment3 Interventions
Start with Stage 1 HERS intervention; patient attends baseline colposcopy appointment, no Stage 2 intervention. Continue with Stage 3 HERS intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS+HC intervention.
Group VIII: Stage 1 and 3 HERSExperimental Treatment2 Interventions
Start with Stage 1 HERS intervention; patient attends baseline colposcopy appointment, no Stage 2 intervention. Continue with Stage 3 HERS intervention; patient attends 12-month follow-up appointment, no Stage 4 intervention.
Group IX: Stage 1 SoC + Stage 2, 3, and 4 HERSExperimental Treatment4 Interventions
Start with Stage 1 Standard of Care; patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS intervention. Continue with Stage 3 HERS intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS intervention.
Group X: Stage 1 SoC + Stage 2 and 3 HERS + Stage 4 HERS+HCExperimental Treatment4 Interventions
Start with Stage 1 Standard of Care; patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS intervention. Continue with Stage 3 HERS intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS+HC intervention.
Group XI: Stage 1 SoC + Stage 2 and 3 HERSExperimental Treatment3 Interventions
Start with Stage 1 Standard of Care; patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS intervention. Continue with Stage 3 HERS intervention; patient attends 12-month follow-up appointment, no Stage 4 intervention.
Group XII: Stage 1 HERS + Stage 2, 3, and 4 HERS+HCExperimental Treatment4 Interventions
Start with Stage 1 HERS intervention, patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS+HC intervention. Continue with Stage 3 HERS+HC intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS+HC intervention.
Group XIII: Stage 1 HERS + Stage 2 and 3 HERS+HCExperimental Treatment3 Interventions
Start with Stage 1 HERS intervention, patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS+HC intervention. Continue with Stage 3 HERS+HC intervention; patient attends 12-month follow-up appointment, no Stage 4 intervention.

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyOTHER
445 Previous Clinical Trials
65,500 Total Patients Enrolled
Temple UniversityOTHER
315 Previous Clinical Trials
88,355 Total Patients Enrolled
University of South CarolinaOTHER
220 Previous Clinical Trials
119,525 Total Patients Enrolled
~364 spots leftby Apr 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top